Hypercholesterolemia – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Hypercholesterolemia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hypercholesterolemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercholesterolemia. Hypercholesterolemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Summary
Global Markets Direct’s, 'Hypercholesterolemia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hypercholesterolemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercholesterolemia. Hypercholesterolemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Hypercholesterolemia.
- A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypercholesterolemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hypercholesterolemia Overview
Therapeutics Development
An Overview of Pipeline Products for Hypercholesterolemia
Hypercholesterolemia Therapeutics under Development by Companies
Hypercholesterolemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hypercholesterolemia Therapeutics – Products under Development by Companies
Hypercholesterolemia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Hypercholesterolemia Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Amgen Inc.
Eli Lilly and Company
Tekmira Pharmaceuticals Corp.
Merck & Co., Inc.
Novartis AG
MDRNA, Inc.
Pfizer Inc.
Santaris Pharma A/S
Aegerion Pharmaceuticals, Inc.
ReGenX Biosciences, LLC
Alnylam Pharmaceuticals, Inc
Regeneron Pharmaceuticals, Inc.
Ache Laboratorios Farmaceuticos S/A
Relypsa, Inc.
Esperion Therapeutics, Inc.
Madeira Therapeutics
Hypercholesterolemia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
anacetrapib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mipomersen sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0524A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0524A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPC-4955 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THR-ß 3196 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-PCS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TKM-ApoB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEGR-733 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETC-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDR-04227 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alipogene tiparvovec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alipogene tiparvovec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REGN-727 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-823778 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-2484595 + Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2484595 + Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2484595 + Rosuvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0653C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCQ-908 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-145 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evacetrapib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-770767 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RN-316 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
atorvastatin calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RLY-106 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REGN727 + Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
atorvastatin calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ezetimibe - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rosuvastatin calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-962476 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
1D05-FAB - DRUG PROFILE
Product Description
Mechanism of Action
R&D Progress
Rosuvastatin + Ezetimibe - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LGT-209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Familial Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HeartVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-852927 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypercholesterolemia Therapeutics – Drug Profile Updates
Hypercholesterolemia Therapeutics – Discontinued Products
Hypercholesterolemia Therapeutics - Dormant Products
Hypercholesterolemia – Product Development Milestones
Featured News & Press Releases
Aug 26, 2012: Merck Provides Update On Anacetrapib Development Program
Aug 26, 2012: Merck Provides Update On Tredaptive Development Program
Aug 14, 2012: Aegerion Pharma Announces Date Of FDA Advisory Committee Review Of Lomitapide NDA
Aug 13, 2012: Ranbaxy Shifts Production Of Generic Lipitor To Mohali, India
Jul 20, 2012: Sanofi And Regeneron Pharma Launch Comprehensive Phase III Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
Jun 06, 2012: Tai Tien Pharma Launches Pitavastatin Calcium In Taiwan
May 29, 2012: Aegerion Announces Oral Presentation Of Phase III Lomitapide Data At European Atherosclerosis Society Conference
May 29, 2012: AstraZeneca Continues To Support Patients On CRESTOR
May 29, 2012: Genzyme And Isis Announce Filing Of NDA For KYNAMRO In Homozygous Familial Hypercholesterolemia
May 26, 2012: Sanofi And Regeneron Pharma Announce Publication Of Positive Phase II Results Of Lipid-Lowering PCSK9 Antibody In The Lancet
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Hypercholesterolemia, H2 2012
Products under Development for Hypercholesterolemia – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Bristol-Myers Squibb Company, H2 2012
Genzyme Corporation, H2 2012
Amgen Inc., H2 2012
Eli Lilly and Company, H2 2012
Tekmira Pharmaceuticals Corp., H2 2012
Merck & Co., Inc., H2 2012
Novartis AG, H2 2012
MDRNA, Inc., H2 2012
Pfizer Inc., H2 2012
Santaris Pharma A/S, H2 2012
Aegerion Pharmaceuticals, Inc., H2 2012
ReGenX Biosciences, LLC, H2 2012
Alnylam Pharmaceuticals, Inc, H2 2012
Regeneron Pharmaceuticals, Inc., H2 2012
Ache Laboratorios Farmaceuticos S/A, H2 2012
Relypsa, Inc., H2 2012
Esperion Therapeutics, Inc., H2 2012
Madeira Therapeutics, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Hypercholesterolemia Therapeutics – Drug Profile Updates
Hypercholesterolemia Therapeutics – Discontinued Products
Hypercholesterolemia Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Hypercholesterolemia, H2 2012
Products under Development for Hypercholesterolemia – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Hypercholesterolemia Overview
Therapeutics Development
An Overview of Pipeline Products for Hypercholesterolemia
Hypercholesterolemia Therapeutics under Development by Companies
Hypercholesterolemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hypercholesterolemia Therapeutics – Products under Development by Companies
Hypercholesterolemia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Hypercholesterolemia Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Amgen Inc.
Eli Lilly and Company
Tekmira Pharmaceuticals Corp.
Merck & Co., Inc.
Novartis AG
MDRNA, Inc.
Pfizer Inc.
Santaris Pharma A/S
Aegerion Pharmaceuticals, Inc.
ReGenX Biosciences, LLC
Alnylam Pharmaceuticals, Inc
Regeneron Pharmaceuticals, Inc.
Ache Laboratorios Farmaceuticos S/A
Relypsa, Inc.
Esperion Therapeutics, Inc.
Madeira Therapeutics
Hypercholesterolemia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
anacetrapib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mipomersen sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0524A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0524A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPC-4955 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THR-ß 3196 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-PCS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TKM-ApoB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEGR-733 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETC-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDR-04227 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alipogene tiparvovec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alipogene tiparvovec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REGN-727 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-823778 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-2484595 + Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2484595 + Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2484595 + Rosuvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0653C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCQ-908 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-145 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evacetrapib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-770767 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RN-316 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
atorvastatin calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RLY-106 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REGN727 + Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
atorvastatin calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ezetimibe - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rosuvastatin calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-962476 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
1D05-FAB - DRUG PROFILE
Product Description
Mechanism of Action
R&D Progress
Rosuvastatin + Ezetimibe - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LGT-209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Familial Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HeartVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-852927 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypercholesterolemia Therapeutics – Drug Profile Updates
Hypercholesterolemia Therapeutics – Discontinued Products
Hypercholesterolemia Therapeutics - Dormant Products
Hypercholesterolemia – Product Development Milestones
Featured News & Press Releases
Aug 26, 2012: Merck Provides Update On Anacetrapib Development Program
Aug 26, 2012: Merck Provides Update On Tredaptive Development Program
Aug 14, 2012: Aegerion Pharma Announces Date Of FDA Advisory Committee Review Of Lomitapide NDA
Aug 13, 2012: Ranbaxy Shifts Production Of Generic Lipitor To Mohali, India
Jul 20, 2012: Sanofi And Regeneron Pharma Launch Comprehensive Phase III Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
Jun 06, 2012: Tai Tien Pharma Launches Pitavastatin Calcium In Taiwan
May 29, 2012: Aegerion Announces Oral Presentation Of Phase III Lomitapide Data At European Atherosclerosis Society Conference
May 29, 2012: AstraZeneca Continues To Support Patients On CRESTOR
May 29, 2012: Genzyme And Isis Announce Filing Of NDA For KYNAMRO In Homozygous Familial Hypercholesterolemia
May 26, 2012: Sanofi And Regeneron Pharma Announce Publication Of Positive Phase II Results Of Lipid-Lowering PCSK9 Antibody In The Lancet
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Hypercholesterolemia, H2 2012
Products under Development for Hypercholesterolemia – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Bristol-Myers Squibb Company, H2 2012
Genzyme Corporation, H2 2012
Amgen Inc., H2 2012
Eli Lilly and Company, H2 2012
Tekmira Pharmaceuticals Corp., H2 2012
Merck & Co., Inc., H2 2012
Novartis AG, H2 2012
MDRNA, Inc., H2 2012
Pfizer Inc., H2 2012
Santaris Pharma A/S, H2 2012
Aegerion Pharmaceuticals, Inc., H2 2012
ReGenX Biosciences, LLC, H2 2012
Alnylam Pharmaceuticals, Inc, H2 2012
Regeneron Pharmaceuticals, Inc., H2 2012
Ache Laboratorios Farmaceuticos S/A, H2 2012
Relypsa, Inc., H2 2012
Esperion Therapeutics, Inc., H2 2012
Madeira Therapeutics, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Hypercholesterolemia Therapeutics – Drug Profile Updates
Hypercholesterolemia Therapeutics – Discontinued Products
Hypercholesterolemia Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Hypercholesterolemia, H2 2012
Products under Development for Hypercholesterolemia – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
